declar
outbreak
public
health
emerg
intern
concern
howev
date
hardli
studi
character
immun
respons
especi
adapt
immun
respons
infect
studi
collect
blood
patient
recent
becom
virusfre
therefor
discharg
analyz
antibodi
cell
respons
observ
humor
cellular
immun
patient
detect
newli
discharg
patient
suggest
particip
immunemedi
protect
viral
infect
howev
followup
patient
week
post
discharg
exhibit
high
titer
igg
antibodi
low
level
virusspecif
cell
suggest
may
enter
quiescent
state
work
thu
provid
basi
analysi
protect
immun
understand
pathogenesi
especi
sever
case
also
implic
design
effect
vaccin
protect
treat
infect
medrxiv
preprint
pbmc
wash
pb
plu
fb
gibco
grand
island
ny
fc
block
reagent
meltenyi
biotec
inc
auburn
ca
ad
follow
wash
pb
plu
fb
cell
incub
min
ice
biolegend
biolegend
bd
biolegend
antial
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
medrxiv
preprint
biolegend
livedead
fixabl
aqua
dye
ebiosci
wash
twice
pb
plu
fb
store
acquir
fac
vers
bd
bioscienc
san
jose
ca
data
analyz
use
flowjo
softwar
version
tree
star
inc
ashland
prism
softwar
use
statist
analysi
student
test
perform
twogroup
analysi
pearson
correl
coeffici
calcul
p
valu
less
consid
statist
signific
end
patient
coronaviru
diseas
covid
identifi
wuhan
china
infect
novel
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
declar
outbreak
public
health
emerg
intern
concern
genom
sequenc
bear
ident
bat
coronaviru
sarscov
respect
like
sarscov
merscov
belong
beta
genu
coronaviru
corornavirida
famili
clinic
sever
paper
show
patient
develop
lymphopenia
well
pneumonia
higher
plasma
level
proinflammatori
cytokin
sever
case
suggest
host
immun
system
involv
pathogenesi
patient
infect
sarscov
merscov
previous
report
antibodi
respons
exhibit
defect
express
type
ii
interferon
ifn
indic
poor
protect
immun
respons
howev
date
hardli
studi
character
immun
respons
especi
adapt
immun
respons
infect
one
patient
shown
nucleocapsid
protein
np
specif
antibodi
respons
igm
peak
day
diseas
onset
switch
igg
week
suggest
involv
humor
immun
lymphocyt
respons
unclear
studi
collect
blood
patient
recent
becom
virusfre
therefor
discharg
analyz
antibodi
cell
respons
clinic
patholog
characterist
patient
studi
shown
tabl
patient
initi
show
mild
symptom
via
ct
scan
posit
nucleic
acid
test
patient
newli
discharg
remain
week
post
discharg
followup
patient
patient
line
previou
report
patient
show
lymphopenia
normal
rang
cell
per
l
howev
two
travel
wuhan
citi
within
past
month
one
serum
obtain
outbreak
healthi
donor
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
addit
healthi
donor
close
contact
patient
recruit
studi
human
ab
serum
gemcel
ca
use
neg
control
order
detect
antivir
immun
respons
first
construct
recombin
link
copi
tag
cterminu
np
vector
biom
cat
number
escherichia
coli
transform
lyse
test
coomassi
blue
stain
confirm
np
express
kda
np
purifi
ninta
affin
chromatographi
gel
filtrat
puriti
np
approxim
figur
presenc
np
subsequ
confirm
antiflag
antibodi
figur
rbd
region
protein
srbd
main
proteas
doi
http
produc
baculoviru
insect
express
system
purifi
reach
puriti
figur
use
sera
patient
healthi
donor
igg
igm
np
main
proteas
srbd
antigen
analyz
signific
antibodi
respons
main
proteas
sera
sever
patient
data
shown
suggest
may
serv
antigen
humor
immun
thu
focus
np
srbd
serum
patient
human
ab
serum
titrat
order
determin
optim
dilut
data
shown
dilut
use
igm
igg
npand
srbdspecif
igm
igg
antibodi
detect
sera
newli
discharg
patient
compar
healthi
donor
group
figur
igg
antibodi
also
obvious
observ
igm
followup
patient
compar
healthi
donor
figur
taken
togeth
find
indic
patient
mount
igg
igm
respons
protein
especi
np
srbd
also
suggest
infect
patient
could
maintain
igg
level
least
two
week
sinc
rbd
domain
protein
shown
bind
human
receptor
exist
antibodi
may
suggest
neutral
infect
assess
perform
pseudoviru
particlebas
neutral
assay
shown
figur
patient
within
discharg
group
high
level
neutral
antibodi
titer
result
demonstr
recent
discharg
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
protect
humor
immun
except
patient
followup
patient
lower
level
neutral
antibodi
titer
recent
discharg
patient
though
posit
except
patient
neg
whether
protect
humor
immun
maintain
need
investig
explor
cellular
immun
respons
isol
pbmc
whole
blood
phenotyp
analyz
flow
cytometri
figur
found
compar
discharg
patient
trend
toward
increas
frequenc
nk
cell
followup
patient
figur
howev
signific
differ
term
percentag
cell
among
two
group
healthi
donor
assess
virusspecif
cellular
immun
treat
pbmc
recombin
np
main
proteas
srbd
follow
ifng
elispot
analysi
result
consid
posit
least
increas
number
ifngsecret
cell
subject
healthi
donor
shown
figur
compar
healthi
donor
number
ifngsecret
npspecif
cell
patient
much
higher
patient
suggest
develop
cell
respons
note
patient
develop
strong
humor
cellular
immun
respons
main
proteasespecif
cell
detect
patient
patient
show
srbdspecif
cell
although
number
ifngsecret
srbd
specif
cell
much
lower
npspecif
cell
could
detect
patient
viral
protein
srbd
thu
elicit
humor
immun
may
result
blockad
receptor
bind
viral
entri
host
cell
also
induc
cell
immun
respons
suggest
srbd
promis
target
vaccin
followup
patient
patient
show
lymphopenia
treatment
still
high
number
ifngsecret
cell
respons
np
main
proteas
srbd
figur
suggest
antivir
cell
may
maintain
high
number
pbmc
recov
patient
interestingli
combin
patient
analysi
signific
correl
neutral
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
summari
provid
first
analysi
humor
cellular
immun
detect
newli
discharg
patient
suggest
particip
immunemedi
protect
viral
infect
howev
followup
patient
exhibit
high
titer
igg
antibodi
low
level
virusspecif
cell
suggest
may
enter
quiescent
state
work
thu
provid
basi
analysi
protect
immun
understand
pathogenesi
especi
sever
case
also
implic
design
effect
vaccin
protect
treat
infect
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
procedur
follow
accord
ethic
standard
respons
committe
human
experiment
institut
review
board
tsinghua
univers
helsinki
declar
revis
inform
consent
obtain
subject
includ
studi
patient
data
anonym
studi
inclus
blood
sampl
patient
healthi
donor
obtain
chui
yang
liu
hospit
affili
tsinghua
univers
beij
recombin
histag
np
express
e
coli
pbmc
isol
anticoagul
blood
use
ficollhypaqu
gradient
ge
healthcar
life
scienc
philadelphia
pa
previous
describ
facil
amm
igmigg
test
elisa
plate
coat
overnight
recombin
np
srbd
ngwell
sera
patient
incub
h
antihuman
iggbiotin
conjug
monoclon
antibodi
sino
biolog
inc
wayn
pa
streptavidinhrp
use
dilut
respect
antihuman
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
igmhrp
conjug
monoclon
antibodi
inova
diagnost
inc
san
diego
ca
od
valu
calcul
pseudoviru
express
protein
produc
describ
previous
gppcagg
cotransfect
cell
hour
later
pseudoviruscontain
supernat
mix
least
serial
dilut
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
